Literature DB >> 34149261

Cannabidiol (CBD) Use in Type 2 Diabetes: A Case Report.

Raymond G Mattes1, Melchor L Espinosa1, Sam S Oh1, Elizabeth M Anatrella2, Elizabeth M Urteaga1.   

Abstract

Entities:  

Year:  2021        PMID： 34149261      PMCID： PMC8178711          DOI： 10.2337/ds20-0023

Source DB:  PubMed          Journal:  Diabetes Spectr        ISSN： 1040-9165


× No keyword cloud information.
  11 in total

Review 1.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

Authors:  Penny F Whiting; Robert F Wolff; Sohan Deshpande; Marcello Di Nisio; Steven Duffy; Adrian V Hernandez; J Christiaan Keurentjes; Shona Lang; Kate Misso; Steve Ryder; Simone Schmidlkofer; Marie Westwood; Jos Kleijnen
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

2.  Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse.

Authors:  Alaa Al Saabi; Delphine Allorge; François-Ludovic Sauvage; Gilles Tournel; Jean-Michel Gaulier; Pierre Marquet; Nicolas Picard
Journal:  Drug Metab Dispos       Date:  2012-12-10       Impact factor: 3.922

3.  Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation.

Authors:  Gregory I Liou
Journal:  World J Diabetes       Date:  2010-03-15

4.  Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

Authors:  L Weiss; M Zeira; S Reich; M Har-Noy; R Mechoulam; S Slavin; R Gallily
Journal:  Autoimmunity       Date:  2006-03       Impact factor: 2.815

5.  Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; György Haskó; Lucas Liaudet; Viktor R Drel; Irina G Obrosova; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-23       Impact factor: 4.733

6.  Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; Vivek Patel; Keita Saito; Shingo Matsumoto; Yoshihiro Kashiwaya; Béla Horváth; Bani Mukhopadhyay; Lauren Becker; György Haskó; Lucas Liaudet; David A Wink; Aristidis Veves; Raphael Mechoulam; Pál Pacher
Journal:  J Am Coll Cardiol       Date:  2010-12-14       Impact factor: 24.094

Review 7.  Cannabinoid receptors: where they are and what they do.

Authors:  K Mackie
Journal:  J Neuroendocrinol       Date:  2008-05       Impact factor: 3.627

Review 8.  Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.

Authors:  Stephen M Stout; Nina M Cimino
Journal:  Drug Metab Rev       Date:  2013-10-25       Impact factor: 4.518

9.  Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis.

Authors:  Fabricio A Pamplona; Lorenzo Rolim da Silva; Ana Carolina Coan
Journal:  Front Neurol       Date:  2018-09-12       Impact factor: 4.003

10.  An interaction between warfarin and cannabidiol, a case report.

Authors:  Leslie Grayson; Brannon Vines; Kate Nichol; Jerzy P Szaflarski
Journal:  Epilepsy Behav Case Rep       Date:  2017-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.